Edwards Lifesciences: Held Back by $95.5 Fair Value Target
By stockpickr AI | March 1, 2026 | 10 min read
Investment Summary
Edwards Lifesciences (Healthcare) appears to be fairly valued to slightly overvalued based on the DCF analysis, supported by a strong financial standing and market leadership in structural heart devices.
Investment Recommendation
Hold
Fair Value: $95.50
Current Price: $92.11
Upside/Downside: +3.68%
The calculated intrinsic value suggests the current stock price is near fair value. While the long-term growth story remains compelling due to structural heart trends, the current WACC and projected growth rates do not provide a significant margin of safety at the present trading level.
Key Metrics
- Market Cap: $57.32B
- P/E Ratio: 42.46x
- Forward P/E: 21.74x
- Revenue Growth (YoY): 9.1%
- Net Margin: 13.7%
- ROE: 16.9%
- Debt/Equity: 0.26
- Dividend Yield: 0.59%
Strengths
- Market leader in Transcatheter Aortic Valve Replacement (TAVR) with significant market share.
- Strong historical revenue growth averaging around 9% YoY recently, demonstrating market penetration.
- Solid net margin around 13.7%, indicating efficient operations.
- Robust balance sheet with manageable debt levels (Debt/Equity ratio of 0.26).
Risk Factors
- Intense competition from Medtronic and Abbott in the rapidly evolving structural heart space.
- Reliance on new product adoption and maintaining favorable reimbursement rates for procedures.
- Potential headwinds from global supply chain constraints impacting production costs.
- Valuation metrics (P/E ratio of 42.46) suggest high growth expectations are already priced in.